Bruker Announces the Designation and Certification of its RAID-M Handheld Chemical Detector Under the SAFETY ACT as an Approved Product for Homeland Security
BILLERICA, Mass.--(BUSINESS WIRE)--Jan. 30, 2006--Bruker Daltonics NBC Detection Corp., an operating company of Bruker BioSciences Corporation (NASDAQ: BRKR), today announces that the Department of Homeland Security has granted Designation and Certification of the RAID-M as an approved product under the Support Anti-terrorism by Fostering Effective Technologies Act of 2002 (the SAFETY Act). The RAID-M received both Designation as a Qualified Anti-Terrorism Technology and Certification as an Approved Product for Homeland Security. This is the culmination of a vigorous and meticulous evaluation of the efficacy of the RAID-M that took several months.
Frank Thibodeau, Vice President, commented: "This Certification by the Department of Homeland Security is more evidence that the RAID-M is considered by many to be the best handheld chemical detector in the world today. It is really a great tool in the hands of our country's first responders. Along with many independent tests by government agencies around the world, the DHS Certification lends even more credibility and confidence in the RAID-M as the premier chemical and toxic industrial detector on the market."
By receiving the Designation and Certification, Bruker Daltonics, its customers and its suppliers will enjoy significant product liability protections under the Safety Act.
ABOUT BRUKER BIOSCIENCES
Bruker BioSciences, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. For more information about Bruker BioSciences Corporation, please visit www.bruker-biosciences.com
CAUTIONARY STATEMENT
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companies' reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the companies' products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2004, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.
MULTIMEDIA AVAILABLE:
www.businesswire.com/cgi-bin/mmg.cgi
CONTACT:
Bruker BioSciences Corp.
Michael Willett, 978-663-3660, ext. 1411
Investor and Public Relations Officer
Michael.Willett@bruker.com
SOURCE:
Bruker BioSciences Corporation
